nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRC—urinary bladder cancer	0.278	0.598	CbGaD
Bosutinib—EGFR—urinary bladder cancer	0.187	0.402	CbGaD
Bosutinib—Vandetanib—SRC—urinary bladder cancer	0.00158	0.433	CrCbGaD
Bosutinib—Vandetanib—EGFR—urinary bladder cancer	0.00106	0.291	CrCbGaD
Bosutinib—Gefitinib—EGFR—urinary bladder cancer	0.00101	0.276	CrCbGaD
Bosutinib—WEE1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000716	0.141	CbGdCrCtD
Bosutinib—STK24—Teniposide—Etoposide—urinary bladder cancer	0.000426	0.084	CbGdCrCtD
Bosutinib—CSNK1E—urethra—urinary bladder cancer	0.000324	0.00196	CbGeAlD
Bosutinib—MAP2K5—prostate gland—urinary bladder cancer	0.000322	0.00195	CbGeAlD
Bosutinib—PTK2—smooth muscle tissue—urinary bladder cancer	0.00032	0.00194	CbGeAlD
Bosutinib—RPS6KB1—epithelium—urinary bladder cancer	0.00032	0.00194	CbGeAlD
Bosutinib—ROCK1—female reproductive system—urinary bladder cancer	0.000319	0.00194	CbGeAlD
Bosutinib—SIK1—urethra—urinary bladder cancer	0.000318	0.00193	CbGeAlD
Bosutinib—IRAK4—urethra—urinary bladder cancer	0.000318	0.00193	CbGeAlD
Bosutinib—ERBB3—renal system—urinary bladder cancer	0.000318	0.00193	CbGeAlD
Bosutinib—MAP2K2—renal system—urinary bladder cancer	0.000317	0.00192	CbGeAlD
Bosutinib—EPHA4—urethra—urinary bladder cancer	0.000315	0.00191	CbGeAlD
Bosutinib—CSF1R—prostate gland—urinary bladder cancer	0.000314	0.0019	CbGeAlD
Bosutinib—IRAK1—smooth muscle tissue—urinary bladder cancer	0.000314	0.0019	CbGeAlD
Bosutinib—FER—vagina—urinary bladder cancer	0.000313	0.0019	CbGeAlD
Bosutinib—EPHA5—vagina—urinary bladder cancer	0.000313	0.0019	CbGeAlD
Bosutinib—ULK3—urethra—urinary bladder cancer	0.000311	0.00189	CbGeAlD
Bosutinib—MAP2K2—urethra—urinary bladder cancer	0.000311	0.00189	CbGeAlD
Bosutinib—BMPR2—female reproductive system—urinary bladder cancer	0.00031	0.00188	CbGeAlD
Bosutinib—TBK1—renal system—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—PTK2—renal system—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—RPS6KB1—smooth muscle tissue—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—STK36—female reproductive system—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—EPHB3—female reproductive system—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—YES1—seminal vesicle—urinary bladder cancer	0.000308	0.00187	CbGeAlD
Bosutinib—MAP4K1—vagina—urinary bladder cancer	0.000307	0.00186	CbGeAlD
Bosutinib—MAP3K7—urethra—urinary bladder cancer	0.000306	0.00186	CbGeAlD
Bosutinib—BTK—vagina—urinary bladder cancer	0.000305	0.00185	CbGeAlD
Bosutinib—AXL—smooth muscle tissue—urinary bladder cancer	0.000305	0.00185	CbGeAlD
Bosutinib—CYP3A4—urine—urinary bladder cancer	0.000304	0.00184	CbGeAlD
Bosutinib—TAOK3—seminal vesicle—urinary bladder cancer	0.000304	0.00184	CbGeAlD
Bosutinib—TBK1—urethra—urinary bladder cancer	0.000303	0.00184	CbGeAlD
Bosutinib—PTK2—urethra—urinary bladder cancer	0.000303	0.00184	CbGeAlD
Bosutinib—EPHB4—epithelium—urinary bladder cancer	0.000302	0.00183	CbGeAlD
Bosutinib—TLK1—lymph node—urinary bladder cancer	0.000302	0.00183	CbGeAlD
Bosutinib—MAP4K4—female reproductive system—urinary bladder cancer	0.000299	0.00181	CbGeAlD
Bosutinib—PRKCQ—lymph node—urinary bladder cancer	0.000298	0.00181	CbGeAlD
Bosutinib—EPHA2—epithelium—urinary bladder cancer	0.000297	0.0018	CbGeAlD
Bosutinib—MAP4K2—vagina—urinary bladder cancer	0.000297	0.0018	CbGeAlD
Bosutinib—RPS6KB1—renal system—urinary bladder cancer	0.000297	0.0018	CbGeAlD
Bosutinib—BCR—female reproductive system—urinary bladder cancer	0.000296	0.0018	CbGeAlD
Bosutinib—MAP3K12—female reproductive system—urinary bladder cancer	0.000294	0.00178	CbGeAlD
Bosutinib—STK3—vagina—urinary bladder cancer	0.000293	0.00177	CbGeAlD
Bosutinib—ERBB4—vagina—urinary bladder cancer	0.000293	0.00177	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—urinary bladder cancer	0.000291	0.00177	CbGeAlD
Bosutinib—RPS6KB1—urethra—urinary bladder cancer	0.000291	0.00177	CbGeAlD
Bosutinib—FGR—urethra—urinary bladder cancer	0.00029	0.00176	CbGeAlD
Bosutinib—LCK—urethra—urinary bladder cancer	0.00029	0.00176	CbGeAlD
Bosutinib—MAP2K1—female reproductive system—urinary bladder cancer	0.000288	0.00175	CbGeAlD
Bosutinib—STK35—female reproductive system—urinary bladder cancer	0.000288	0.00175	CbGeAlD
Bosutinib—AXL—urethra—urinary bladder cancer	0.000288	0.00175	CbGeAlD
Bosutinib—CSK—female reproductive system—urinary bladder cancer	0.000286	0.00174	CbGeAlD
Bosutinib—FYN—smooth muscle tissue—urinary bladder cancer	0.000285	0.00173	CbGeAlD
Bosutinib—CSNK1A1—female reproductive system—urinary bladder cancer	0.000285	0.00173	CbGeAlD
Bosutinib—CLK1—female reproductive system—urinary bladder cancer	0.000283	0.00171	CbGeAlD
Bosutinib—BMPR2—vagina—urinary bladder cancer	0.000281	0.0017	CbGeAlD
Bosutinib—EPHB4—renal system—urinary bladder cancer	0.000281	0.0017	CbGeAlD
Bosutinib—BMX—lymph node—urinary bladder cancer	0.000279	0.00169	CbGeAlD
Bosutinib—DSTYK—lymph node—urinary bladder cancer	0.000279	0.00169	CbGeAlD
Bosutinib—CLK3—lymph node—urinary bladder cancer	0.000279	0.00169	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—urinary bladder cancer	0.000279	0.00169	CbGeAlD
Bosutinib—PDGFRB—prostate gland—urinary bladder cancer	0.000279	0.00169	CbGeAlD
Bosutinib—STK36—vagina—urinary bladder cancer	0.000278	0.00169	CbGeAlD
Bosutinib—EPHB3—vagina—urinary bladder cancer	0.000278	0.00169	CbGeAlD
Bosutinib—CAMK2G—female reproductive system—urinary bladder cancer	0.000278	0.00168	CbGeAlD
Bosutinib—BMP2K—female reproductive system—urinary bladder cancer	0.000278	0.00168	CbGeAlD
Bosutinib—SLK—urethra—urinary bladder cancer	0.000278	0.00168	CbGeAlD
Bosutinib—BLK—lymph node—urinary bladder cancer	0.000276	0.00167	CbGeAlD
Bosutinib—EPHB4—urethra—urinary bladder cancer	0.000276	0.00167	CbGeAlD
Bosutinib—MERTK—vagina—urinary bladder cancer	0.000275	0.00167	CbGeAlD
Bosutinib—LRRK2—female reproductive system—urinary bladder cancer	0.000275	0.00167	CbGeAlD
Bosutinib—FYN—renal system—urinary bladder cancer	0.000275	0.00167	CbGeAlD
Bosutinib—CASK—Teniposide—Etoposide—urinary bladder cancer	0.000274	0.0541	CbGdCrCtD
Bosutinib—PHKG1—lymph node—urinary bladder cancer	0.000273	0.00166	CbGeAlD
Bosutinib—CASK—lymph node—urinary bladder cancer	0.000273	0.00166	CbGeAlD
Bosutinib—MAP2K5—seminal vesicle—urinary bladder cancer	0.000272	0.00165	CbGeAlD
Bosutinib—EPHA2—urethra—urinary bladder cancer	0.00027	0.00164	CbGeAlD
Bosutinib—EIF2AK1—lymph node—urinary bladder cancer	0.00027	0.00164	CbGeAlD
Bosutinib—MAP4K4—vagina—urinary bladder cancer	0.00027	0.00164	CbGeAlD
Bosutinib—FYN—urethra—urinary bladder cancer	0.00027	0.00164	CbGeAlD
Bosutinib—NUAK2—vagina—urinary bladder cancer	0.000268	0.00163	CbGeAlD
Bosutinib—BCR—vagina—urinary bladder cancer	0.000268	0.00163	CbGeAlD
Bosutinib—PTK2B—female reproductive system—urinary bladder cancer	0.000268	0.00163	CbGeAlD
Bosutinib—MAP3K12—vagina—urinary bladder cancer	0.000266	0.00161	CbGeAlD
Bosutinib—CSF1R—seminal vesicle—urinary bladder cancer	0.000266	0.00161	CbGeAlD
Bosutinib—TXK—lymph node—urinary bladder cancer	0.000264	0.0016	CbGeAlD
Bosutinib—CSNK1E—female reproductive system—urinary bladder cancer	0.000264	0.0016	CbGeAlD
Bosutinib—MAP4K5—urethra—urinary bladder cancer	0.000264	0.0016	CbGeAlD
Bosutinib—MAP3K3—urethra—urinary bladder cancer	0.000264	0.0016	CbGeAlD
Bosutinib—VRK2—lymph node—urinary bladder cancer	0.000262	0.00159	CbGeAlD
Bosutinib—FES—lymph node—urinary bladder cancer	0.000262	0.00159	CbGeAlD
Bosutinib—STK35—vagina—urinary bladder cancer	0.000261	0.00158	CbGeAlD
Bosutinib—SIK1—female reproductive system—urinary bladder cancer	0.00026	0.00157	CbGeAlD
Bosutinib—CSK—vagina—urinary bladder cancer	0.000259	0.00157	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—urinary bladder cancer	0.000258	0.00156	CbGeAlD
Bosutinib—CSNK1A1—vagina—urinary bladder cancer	0.000257	0.00156	CbGeAlD
Bosutinib—SRC—epithelium—urinary bladder cancer	0.000257	0.00156	CbGeAlD
Bosutinib—EPHA4—female reproductive system—urinary bladder cancer	0.000257	0.00156	CbGeAlD
Bosutinib—SYK—lymph node—urinary bladder cancer	0.000257	0.00156	CbGeAlD
Bosutinib—TNIK—lymph node—urinary bladder cancer	0.000257	0.00156	CbGeAlD
Bosutinib—HCK—vagina—urinary bladder cancer	0.000256	0.00155	CbGeAlD
Bosutinib—CLK1—vagina—urinary bladder cancer	0.000256	0.00155	CbGeAlD
Bosutinib—ERBB3—female reproductive system—urinary bladder cancer	0.000255	0.00154	CbGeAlD
Bosutinib—CDK2—lymph node—urinary bladder cancer	0.000254	0.00154	CbGeAlD
Bosutinib—ABL2—vagina—urinary bladder cancer	0.000254	0.00154	CbGeAlD
Bosutinib—ULK3—female reproductive system—urinary bladder cancer	0.000254	0.00154	CbGeAlD
Bosutinib—MAP2K2—female reproductive system—urinary bladder cancer	0.000254	0.00154	CbGeAlD
Bosutinib—MAP3K2—female reproductive system—urinary bladder cancer	0.000252	0.00153	CbGeAlD
Bosutinib—STK26—lymph node—urinary bladder cancer	0.000252	0.00153	CbGeAlD
Bosutinib—CAMK2G—vagina—urinary bladder cancer	0.000251	0.00152	CbGeAlD
Bosutinib—BMP2K—vagina—urinary bladder cancer	0.000251	0.00152	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000249	0.0491	CbGdCrCtD
Bosutinib—LRRK2—vagina—urinary bladder cancer	0.000249	0.00151	CbGeAlD
Bosutinib—ABL1—prostate gland—urinary bladder cancer	0.000248	0.00151	CbGeAlD
Bosutinib—YES1—renal system—urinary bladder cancer	0.000248	0.0015	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—urinary bladder cancer	0.000248	0.0015	CbGeAlD
Bosutinib—TBK1—female reproductive system—urinary bladder cancer	0.000247	0.0015	CbGeAlD
Bosutinib—PTK2—female reproductive system—urinary bladder cancer	0.000247	0.0015	CbGeAlD
Bosutinib—STK10—renal system—urinary bladder cancer	0.000246	0.00149	CbGeAlD
Bosutinib—TAOK3—renal system—urinary bladder cancer	0.000245	0.00148	CbGeAlD
Bosutinib—CSK—Daunorubicin—Valrubicin—urinary bladder cancer	0.000245	0.0482	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000245	0.0482	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Valrubicin—urinary bladder cancer	0.000245	0.0482	CbGdCrCtD
Bosutinib—YES1—urethra—urinary bladder cancer	0.000244	0.00148	CbGeAlD
Bosutinib—CHEK2—lymph node—urinary bladder cancer	0.000243	0.00148	CbGeAlD
Bosutinib—PTK2B—vagina—urinary bladder cancer	0.000242	0.00147	CbGeAlD
Bosutinib—IRAK1—female reproductive system—urinary bladder cancer	0.000242	0.00147	CbGeAlD
Bosutinib—WEE1—lymph node—urinary bladder cancer	0.000241	0.00146	CbGeAlD
Bosutinib—DMPK—lymph node—urinary bladder cancer	0.000241	0.00146	CbGeAlD
Bosutinib—TAOK3—urethra—urinary bladder cancer	0.00024	0.00146	CbGeAlD
Bosutinib—CSNK1E—vagina—urinary bladder cancer	0.000239	0.00145	CbGeAlD
Bosutinib—SRC—renal system—urinary bladder cancer	0.000239	0.00145	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—urinary bladder cancer	0.000237	0.00144	CbGeAlD
Bosutinib—FGR—female reproductive system—urinary bladder cancer	0.000236	0.00143	CbGeAlD
Bosutinib—PDGFRB—seminal vesicle—urinary bladder cancer	0.000236	0.00143	CbGeAlD
Bosutinib—AXL—female reproductive system—urinary bladder cancer	0.000235	0.00143	CbGeAlD
Bosutinib—IRAK4—vagina—urinary bladder cancer	0.000235	0.00142	CbGeAlD
Bosutinib—EPHA4—vagina—urinary bladder cancer	0.000232	0.00141	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000231	0.0455	CbGdCrCtD
Bosutinib—STK25—lymph node—urinary bladder cancer	0.00023	0.0014	CbGeAlD
Bosutinib—ULK3—vagina—urinary bladder cancer	0.00023	0.00139	CbGeAlD
Bosutinib—EPHA3—lymph node—urinary bladder cancer	0.000229	0.00139	CbGeAlD
Bosutinib—MAP3K7—vagina—urinary bladder cancer	0.000226	0.00137	CbGeAlD
Bosutinib—EPHB4—female reproductive system—urinary bladder cancer	0.000225	0.00136	CbGeAlD
Bosutinib—PLK2—lymph node—urinary bladder cancer	0.000224	0.00136	CbGeAlD
Bosutinib—TBK1—vagina—urinary bladder cancer	0.000223	0.00135	CbGeAlD
Bosutinib—PTK2—vagina—urinary bladder cancer	0.000223	0.00135	CbGeAlD
Bosutinib—SIK3—lymph node—urinary bladder cancer	0.000223	0.00135	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000222	0.00135	CbGeAlD
Bosutinib—EPHA2—female reproductive system—urinary bladder cancer	0.00022	0.00134	CbGeAlD
Bosutinib—FYN—female reproductive system—urinary bladder cancer	0.00022	0.00133	CbGeAlD
Bosutinib—MAP2K5—urethra—urinary bladder cancer	0.000216	0.00131	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—urinary bladder cancer	0.000215	0.0013	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—urinary bladder cancer	0.000215	0.0013	CbGeAlD
Bosutinib—RPS6KB1—vagina—urinary bladder cancer	0.000215	0.0013	CbGeAlD
Bosutinib—STK4—lymph node—urinary bladder cancer	0.000214	0.0013	CbGeAlD
Bosutinib—FGR—vagina—urinary bladder cancer	0.000213	0.00129	CbGeAlD
Bosutinib—LCK—vagina—urinary bladder cancer	0.000213	0.00129	CbGeAlD
Bosutinib—AXL—vagina—urinary bladder cancer	0.000213	0.00129	CbGeAlD
Bosutinib—CAMK1D—lymph node—urinary bladder cancer	0.000212	0.00128	CbGeAlD
Bosutinib—CSF1R—urethra—urinary bladder cancer	0.00021	0.00128	CbGeAlD
Bosutinib—ABL1—seminal vesicle—urinary bladder cancer	0.00021	0.00127	CbGeAlD
Bosutinib—STK24—lymph node—urinary bladder cancer	0.000209	0.00127	CbGeAlD
Bosutinib—PDGFRB—epithelium—urinary bladder cancer	0.000205	0.00124	CbGeAlD
Bosutinib—SLK—vagina—urinary bladder cancer	0.000205	0.00124	CbGeAlD
Bosutinib—EPHB4—vagina—urinary bladder cancer	0.000203	0.00123	CbGeAlD
Bosutinib—FER—lymph node—urinary bladder cancer	0.000203	0.00123	CbGeAlD
Bosutinib—ALK—lymph node—urinary bladder cancer	0.000203	0.00123	CbGeAlD
Bosutinib—EPHA2—vagina—urinary bladder cancer	0.000199	0.00121	CbGeAlD
Bosutinib—FYN—vagina—urinary bladder cancer	0.000199	0.00121	CbGeAlD
Bosutinib—YES1—female reproductive system—urinary bladder cancer	0.000199	0.0012	CbGeAlD
Bosutinib—MAP4K1—lymph node—urinary bladder cancer	0.000198	0.0012	CbGeAlD
Bosutinib—BTK—lymph node—urinary bladder cancer	0.000197	0.0012	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.000197	0.0012	CbGeAlD
Bosutinib—STK10—female reproductive system—urinary bladder cancer	0.000197	0.00119	CbGeAlD
Bosutinib—TAOK3—female reproductive system—urinary bladder cancer	0.000196	0.00119	CbGeAlD
Bosutinib—TNK2—lymph node—urinary bladder cancer	0.000195	0.00118	CbGeAlD
Bosutinib—MAP4K5—vagina—urinary bladder cancer	0.000194	0.00118	CbGeAlD
Bosutinib—MAP3K3—vagina—urinary bladder cancer	0.000194	0.00118	CbGeAlD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—urinary bladder cancer	0.000193	0.038	CbGdCrCtD
Bosutinib—MAP4K2—lymph node—urinary bladder cancer	0.000192	0.00116	CbGeAlD
Bosutinib—SRC—female reproductive system—urinary bladder cancer	0.000191	0.00116	CbGeAlD
Bosutinib—PDGFRB—renal system—urinary bladder cancer	0.00019	0.00115	CbGeAlD
Bosutinib—STK3—lymph node—urinary bladder cancer	0.000189	0.00115	CbGeAlD
Bosutinib—PDGFRB—urethra—urinary bladder cancer	0.000187	0.00113	CbGeAlD
Bosutinib—BMPR2—lymph node—urinary bladder cancer	0.000181	0.0011	CbGeAlD
Bosutinib—STK36—lymph node—urinary bladder cancer	0.00018	0.00109	CbGeAlD
Bosutinib—EPHB3—lymph node—urinary bladder cancer	0.00018	0.00109	CbGeAlD
Bosutinib—YES1—vagina—urinary bladder cancer	0.00018	0.00109	CbGeAlD
Bosutinib—CHEK2—Epirubicin—Valrubicin—urinary bladder cancer	0.000179	0.0353	CbGdCrCtD
Bosutinib—CHEK2—Doxorubicin—Valrubicin—urinary bladder cancer	0.000179	0.0353	CbGdCrCtD
Bosutinib—STK10—vagina—urinary bladder cancer	0.000178	0.00108	CbGeAlD
Bosutinib—MERTK—lymph node—urinary bladder cancer	0.000178	0.00108	CbGeAlD
Bosutinib—TAOK3—vagina—urinary bladder cancer	0.000177	0.00107	CbGeAlD
Bosutinib—ERBB3—Podofilox—Etoposide—urinary bladder cancer	0.000177	0.0349	CbGdCrCtD
Bosutinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000176	0.00107	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—urinary bladder cancer	0.000176	0.00107	CbGeAlD
Bosutinib—MAP4K4—lymph node—urinary bladder cancer	0.000175	0.00106	CbGeAlD
Bosutinib—NUAK2—lymph node—urinary bladder cancer	0.000173	0.00105	CbGeAlD
Bosutinib—BCR—lymph node—urinary bladder cancer	0.000173	0.00105	CbGeAlD
Bosutinib—MAP3K12—lymph node—urinary bladder cancer	0.000172	0.00104	CbGeAlD
Bosutinib—CSF1R—female reproductive system—urinary bladder cancer	0.000171	0.00104	CbGeAlD
Bosutinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000171	0.0337	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000171	0.0337	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000171	0.0337	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000171	0.0337	CbGdCrCtD
Bosutinib—ABL1—renal system—urinary bladder cancer	0.000169	0.00103	CbGeAlD
Bosutinib—MAP2K1—lymph node—urinary bladder cancer	0.000169	0.00102	CbGeAlD
Bosutinib—STK35—lymph node—urinary bladder cancer	0.000169	0.00102	CbGeAlD
Bosutinib—CSK—lymph node—urinary bladder cancer	0.000168	0.00102	CbGeAlD
Bosutinib—CSNK1A1—lymph node—urinary bladder cancer	0.000166	0.00101	CbGeAlD
Bosutinib—ABL1—urethra—urinary bladder cancer	0.000166	0.00101	CbGeAlD
Bosutinib—HCK—lymph node—urinary bladder cancer	0.000165	0.001	CbGeAlD
Bosutinib—CLK1—lymph node—urinary bladder cancer	0.000165	0.001	CbGeAlD
Bosutinib—ABL2—lymph node—urinary bladder cancer	0.000164	0.000997	CbGeAlD
Bosutinib—CAMK2G—lymph node—urinary bladder cancer	0.000162	0.000985	CbGeAlD
Bosutinib—BMP2K—lymph node—urinary bladder cancer	0.000162	0.000985	CbGeAlD
Bosutinib—LRRK2—lymph node—urinary bladder cancer	0.000161	0.000976	CbGeAlD
Bosutinib—EGFR—lymph node—urinary bladder cancer	0.00016	0.000973	CbGeAlD
Bosutinib—MAP2K5—vagina—urinary bladder cancer	0.000159	0.000964	CbGeAlD
Bosutinib—PTK2B—lymph node—urinary bladder cancer	0.000157	0.000951	CbGeAlD
Bosutinib—CSF1R—vagina—urinary bladder cancer	0.000155	0.00094	CbGeAlD
Bosutinib—CSNK1E—lymph node—urinary bladder cancer	0.000154	0.000935	CbGeAlD
Bosutinib—PDGFRB—female reproductive system—urinary bladder cancer	0.000152	0.000922	CbGeAlD
Bosutinib—SIK1—lymph node—urinary bladder cancer	0.000152	0.000921	CbGeAlD
Bosutinib—IRAK4—lymph node—urinary bladder cancer	0.000152	0.000921	CbGeAlD
Bosutinib—EPHA4—lymph node—urinary bladder cancer	0.00015	0.000912	CbGeAlD
Bosutinib—ERBB3—lymph node—urinary bladder cancer	0.000149	0.000903	CbGeAlD
Bosutinib—MAP2K2—lymph node—urinary bladder cancer	0.000149	0.0009	CbGeAlD
Bosutinib—ULK3—lymph node—urinary bladder cancer	0.000149	0.0009	CbGeAlD
Bosutinib—MAP3K2—lymph node—urinary bladder cancer	0.000147	0.000894	CbGeAlD
Bosutinib—MAP3K7—lymph node—urinary bladder cancer	0.000146	0.000886	CbGeAlD
Bosutinib—PTK2—lymph node—urinary bladder cancer	0.000144	0.000876	CbGeAlD
Bosutinib—TBK1—lymph node—urinary bladder cancer	0.000144	0.000876	CbGeAlD
Bosutinib—IRAK1—lymph node—urinary bladder cancer	0.000142	0.000858	CbGeAlD
Bosutinib—Pancytopenia—Methotrexate—urinary bladder cancer	0.000141	0.00103	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000141	0.00103	CcSEcCtD
Bosutinib—Asthenia—Thiotepa—urinary bladder cancer	0.000141	0.00103	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00014	0.00103	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00014	0.00103	CcSEcCtD
Bosutinib—Infection—Etoposide—urinary bladder cancer	0.00014	0.00102	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—urinary bladder cancer	0.000139	0.000842	CbGeAlD
Bosutinib—Influenza—Epirubicin—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Bosutinib—Pruritus—Thiotepa—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Bosutinib—Pain—Fluorouracil—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—urinary bladder cancer	0.000138	0.00101	CcSEcCtD
Bosutinib—FGR—lymph node—urinary bladder cancer	0.000138	0.000837	CbGeAlD
Bosutinib—LCK—lymph node—urinary bladder cancer	0.000138	0.000837	CbGeAlD
Bosutinib—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000138	0.00101	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000138	0.00101	CcSEcCtD
Bosutinib—PDGFRB—vagina—urinary bladder cancer	0.000138	0.000834	CbGeAlD
Bosutinib—AXL—lymph node—urinary bladder cancer	0.000138	0.000834	CbGeAlD
Bosutinib—Dyspnoea—Cisplatin—urinary bladder cancer	0.000137	0.001	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—urinary bladder cancer	0.000137	0.001	CcSEcCtD
Bosutinib—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000136	0.000995	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000136	0.000994	CcSEcCtD
Bosutinib—ABL1—female reproductive system—urinary bladder cancer	0.000136	0.000822	CbGeAlD
Bosutinib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000134	0.000983	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000134	0.00098	CcSEcCtD
Bosutinib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000134	0.000979	CcSEcCtD
Bosutinib—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000134	0.000979	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—urinary bladder cancer	0.000134	0.000978	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—urinary bladder cancer	0.000133	0.000974	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000133	0.000973	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000133	0.000972	CcSEcCtD
Bosutinib—SLK—lymph node—urinary bladder cancer	0.000132	0.000803	CbGeAlD
Bosutinib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000132	0.000969	CcSEcCtD
Bosutinib—Infestation—Methotrexate—urinary bladder cancer	0.000132	0.000969	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—urinary bladder cancer	0.000132	0.000966	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—urinary bladder cancer	0.000132	0.000963	CcSEcCtD
Bosutinib—Pain—Cisplatin—urinary bladder cancer	0.000131	0.000963	CcSEcCtD
Bosutinib—EPHB4—lymph node—urinary bladder cancer	0.000131	0.000797	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000131	0.00096	CcSEcCtD
Bosutinib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00013	0.000955	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—urinary bladder cancer	0.00013	0.000952	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—urinary bladder cancer	0.00013	0.000951	CcSEcCtD
Bosutinib—Dizziness—Thiotepa—urinary bladder cancer	0.00013	0.00095	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000129	0.000945	CcSEcCtD
Bosutinib—EPHA2—lymph node—urinary bladder cancer	0.000129	0.000782	CbGeAlD
Bosutinib—Urticaria—Fluorouracil—urinary bladder cancer	0.000129	0.000944	CcSEcCtD
Bosutinib—FYN—lymph node—urinary bladder cancer	0.000129	0.00078	CbGeAlD
Bosutinib—Influenza—Doxorubicin—urinary bladder cancer	0.000128	0.000941	CcSEcCtD
Bosutinib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000128	0.000939	CcSEcCtD
Bosutinib—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000127	0.000928	CcSEcCtD
Bosutinib—MAP3K3—lymph node—urinary bladder cancer	0.000126	0.000763	CbGeAlD
Bosutinib—MAP4K5—lymph node—urinary bladder cancer	0.000126	0.000763	CbGeAlD
Bosutinib—Dyspnoea—Etoposide—urinary bladder cancer	0.000126	0.00092	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000125	0.000916	CcSEcCtD
Bosutinib—Vomiting—Thiotepa—urinary bladder cancer	0.000125	0.000913	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—urinary bladder cancer	0.000124	0.000912	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000124	0.000907	CcSEcCtD
Bosutinib—Infestation—Epirubicin—urinary bladder cancer	0.000124	0.000907	CcSEcCtD
Bosutinib—Rash—Thiotepa—urinary bladder cancer	0.000124	0.000905	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—urinary bladder cancer	0.000124	0.000905	CcSEcCtD
Bosutinib—Dermatitis—Thiotepa—urinary bladder cancer	0.000124	0.000905	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000123	0.000904	CcSEcCtD
Bosutinib—Headache—Thiotepa—urinary bladder cancer	0.000123	0.0009	CcSEcCtD
Bosutinib—ABL1—vagina—urinary bladder cancer	0.000123	0.000743	CbGeAlD
Bosutinib—Decreased appetite—Etoposide—urinary bladder cancer	0.000122	0.000897	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000122	0.000893	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—urinary bladder cancer	0.000122	0.000891	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000122	0.000891	CcSEcCtD
Bosutinib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000122	0.00089	CcSEcCtD
Bosutinib—Fatigue—Etoposide—urinary bladder cancer	0.000121	0.000889	CcSEcCtD
Bosutinib—Pain—Etoposide—urinary bladder cancer	0.00012	0.000882	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—urinary bladder cancer	0.00012	0.00088	CcSEcCtD
Bosutinib—CHEK2—Teniposide—Etoposide—urinary bladder cancer	0.000119	0.0236	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—urinary bladder cancer	0.000119	0.0236	CbGdCrCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000119	0.000874	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—urinary bladder cancer	0.000119	0.00087	CcSEcCtD
Bosutinib—Asthenia—Gemcitabine—urinary bladder cancer	0.000118	0.000867	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000117	0.000859	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000117	0.000857	CcSEcCtD
Bosutinib—Pruritus—Gemcitabine—urinary bladder cancer	0.000117	0.000855	CcSEcCtD
Bosutinib—Nausea—Thiotepa—urinary bladder cancer	0.000116	0.000853	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—urinary bladder cancer	0.000116	0.000853	CcSEcCtD
Bosutinib—YES1—lymph node—urinary bladder cancer	0.000116	0.000704	CbGeAlD
Bosutinib—Feeling abnormal—Etoposide—urinary bladder cancer	0.000116	0.00085	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000116	0.000846	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—urinary bladder cancer	0.000115	0.000844	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000115	0.000844	CcSEcCtD
Bosutinib—STK10—lymph node—urinary bladder cancer	0.000115	0.000698	CbGeAlD
Bosutinib—Pruritus—Fluorouracil—urinary bladder cancer	0.000115	0.00084	CcSEcCtD
Bosutinib—TAOK3—lymph node—urinary bladder cancer	0.000115	0.000695	CbGeAlD
Bosutinib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000115	0.000839	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—urinary bladder cancer	0.000115	0.000839	CcSEcCtD
Bosutinib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000113	0.000827	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—urinary bladder cancer	0.000113	0.000825	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000112	0.000822	CcSEcCtD
Bosutinib—Urticaria—Etoposide—urinary bladder cancer	0.000112	0.000819	CcSEcCtD
Bosutinib—SRC—lymph node—urinary bladder cancer	0.000112	0.000678	CbGeAlD
Bosutinib—Body temperature increased—Etoposide—urinary bladder cancer	0.000111	0.000815	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—urinary bladder cancer	0.000111	0.000815	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—urinary bladder cancer	0.000111	0.000814	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000111	0.000813	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—urinary bladder cancer	0.000111	0.000811	CcSEcCtD
Bosutinib—Asthenia—Cisplatin—urinary bladder cancer	0.00011	0.000808	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00011	0.000807	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00011	0.000804	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000109	0.000802	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000109	0.0008	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000109	0.000798	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000108	0.000793	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—urinary bladder cancer	0.000107	0.000786	CcSEcCtD
Bosutinib—Dizziness—Fluorouracil—urinary bladder cancer	0.000107	0.000785	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000107	0.000784	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000107	0.000783	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000105	0.00077	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000105	0.00077	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—urinary bladder cancer	0.000105	0.000768	CcSEcCtD
Bosutinib—Rash—Gemcitabine—urinary bladder cancer	0.000104	0.000762	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—urinary bladder cancer	0.000104	0.000761	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—urinary bladder cancer	0.000104	0.000759	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—urinary bladder cancer	0.000103	0.000757	CcSEcCtD
Bosutinib—Headache—Gemcitabine—urinary bladder cancer	0.000103	0.000757	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000103	0.000755	CcSEcCtD
Bosutinib—Vomiting—Fluorouracil—urinary bladder cancer	0.000103	0.000755	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—urinary bladder cancer	0.000103	0.000753	CcSEcCtD
Bosutinib—MAP2K5—lymph node—urinary bladder cancer	0.000103	0.000623	CbGeAlD
Bosutinib—Rash—Fluorouracil—urinary bladder cancer	0.000102	0.000749	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—urinary bladder cancer	0.000102	0.000748	CcSEcCtD
Bosutinib—Headache—Fluorouracil—urinary bladder cancer	0.000102	0.000744	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000102	0.000744	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000101	0.000742	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—urinary bladder cancer	0.000101	0.000741	CcSEcCtD
Bosutinib—Asthenia—Etoposide—urinary bladder cancer	0.000101	0.00074	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000101	0.00074	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000101	0.000738	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—urinary bladder cancer	0.0001	0.000735	CcSEcCtD
Bosutinib—CSF1R—lymph node—urinary bladder cancer	0.0001	0.000608	CbGeAlD
Bosutinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.0001	0.000733	CcSEcCtD
Bosutinib—Back pain—Methotrexate—urinary bladder cancer	0.0001	0.000732	CcSEcCtD
Bosutinib—Pruritus—Etoposide—urinary bladder cancer	9.96e-05	0.00073	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—urinary bladder cancer	9.8e-05	0.000718	CcSEcCtD
Bosutinib—Vomiting—Cisplatin—urinary bladder cancer	9.77e-05	0.000716	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.72e-05	0.000712	CcSEcCtD
Bosutinib—Rash—Cisplatin—urinary bladder cancer	9.69e-05	0.00071	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—urinary bladder cancer	9.68e-05	0.000709	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—urinary bladder cancer	9.67e-05	0.000708	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—urinary bladder cancer	9.64e-05	0.000706	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—urinary bladder cancer	9.63e-05	0.000706	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.59e-05	0.000702	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—urinary bladder cancer	9.59e-05	0.000702	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—urinary bladder cancer	9.55e-05	0.0007	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.54e-05	0.000699	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—urinary bladder cancer	9.47e-05	0.000694	CcSEcCtD
Bosutinib—Back pain—Epirubicin—urinary bladder cancer	9.36e-05	0.000685	CcSEcCtD
Bosutinib—Malaise—Methotrexate—urinary bladder cancer	9.32e-05	0.000683	CcSEcCtD
Bosutinib—Dizziness—Etoposide—urinary bladder cancer	9.31e-05	0.000682	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—urinary bladder cancer	9.29e-05	0.00068	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.27e-05	0.000679	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—urinary bladder cancer	9.25e-05	0.000678	CcSEcCtD
Bosutinib—Nausea—Cisplatin—urinary bladder cancer	9.13e-05	0.000669	CcSEcCtD
Bosutinib—Cough—Methotrexate—urinary bladder cancer	9.02e-05	0.000661	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.97e-05	0.000657	CcSEcCtD
Bosutinib—Vomiting—Etoposide—urinary bladder cancer	8.95e-05	0.000656	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—urinary bladder cancer	8.95e-05	0.000656	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—urinary bladder cancer	8.94e-05	0.000655	CcSEcCtD
Bosutinib—PDGFRB—lymph node—urinary bladder cancer	8.9e-05	0.000539	CbGeAlD
Bosutinib—Rash—Etoposide—urinary bladder cancer	8.88e-05	0.00065	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—urinary bladder cancer	8.87e-05	0.00065	CcSEcCtD
Bosutinib—Headache—Etoposide—urinary bladder cancer	8.82e-05	0.000646	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—urinary bladder cancer	8.8e-05	0.000645	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—urinary bladder cancer	8.8e-05	0.000645	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—urinary bladder cancer	8.8e-05	0.000645	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—urinary bladder cancer	8.76e-05	0.000642	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.74e-05	0.00064	CcSEcCtD
Bosutinib—Malaise—Epirubicin—urinary bladder cancer	8.72e-05	0.000639	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—urinary bladder cancer	8.69e-05	0.000637	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—urinary bladder cancer	8.66e-05	0.000634	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—urinary bladder cancer	8.66e-05	0.000634	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—urinary bladder cancer	8.51e-05	0.0168	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—urinary bladder cancer	8.51e-05	0.0168	CbGdCrCtD
Bosutinib—Cough—Epirubicin—urinary bladder cancer	8.44e-05	0.000618	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.44e-05	0.000618	CcSEcCtD
Bosutinib—Infection—Methotrexate—urinary bladder cancer	8.38e-05	0.000614	CcSEcCtD
Bosutinib—Nausea—Etoposide—urinary bladder cancer	8.37e-05	0.000613	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.3e-05	0.000608	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—urinary bladder cancer	8.27e-05	0.000606	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—urinary bladder cancer	8.27e-05	0.000606	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.26e-05	0.000605	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—urinary bladder cancer	8.24e-05	0.000603	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—urinary bladder cancer	8.24e-05	0.000603	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—urinary bladder cancer	8.24e-05	0.000603	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—urinary bladder cancer	8.19e-05	0.0006	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.18e-05	0.000599	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—urinary bladder cancer	8.14e-05	0.000596	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—urinary bladder cancer	8.07e-05	0.000591	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—urinary bladder cancer	8.01e-05	0.000587	CcSEcCtD
Bosutinib—ABL1—lymph node—urinary bladder cancer	7.93e-05	0.000481	CbGeAlD
Bosutinib—Oedema—Epirubicin—urinary bladder cancer	7.89e-05	0.000578	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.89e-05	0.000578	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—urinary bladder cancer	7.88e-05	0.0155	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—urinary bladder cancer	7.88e-05	0.0155	CbGdCrCtD
Bosutinib—Infection—Epirubicin—urinary bladder cancer	7.84e-05	0.000574	CcSEcCtD
Bosutinib—Cough—Doxorubicin—urinary bladder cancer	7.81e-05	0.000572	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—urinary bladder cancer	7.74e-05	0.000567	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.73e-05	0.000566	CcSEcCtD
Bosutinib—ABCB1—prostate gland—urinary bladder cancer	7.72e-05	0.000468	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.69e-05	0.000563	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—urinary bladder cancer	7.67e-05	0.000562	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—urinary bladder cancer	7.62e-05	0.000558	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—urinary bladder cancer	7.62e-05	0.000558	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—urinary bladder cancer	7.62e-05	0.000558	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.57e-05	0.000554	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—urinary bladder cancer	7.53e-05	0.000551	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—urinary bladder cancer	7.52e-05	0.000551	CcSEcCtD
Bosutinib—CYP3A4—renal system—urinary bladder cancer	7.44e-05	0.000451	CbGeAlD
Bosutinib—Decreased appetite—Methotrexate—urinary bladder cancer	7.33e-05	0.000537	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.3e-05	0.000535	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—urinary bladder cancer	7.3e-05	0.000535	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.28e-05	0.000533	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—urinary bladder cancer	7.27e-05	0.000533	CcSEcCtD
Bosutinib—Infection—Doxorubicin—urinary bladder cancer	7.26e-05	0.000532	CcSEcCtD
Bosutinib—Pain—Methotrexate—urinary bladder cancer	7.21e-05	0.000528	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.19e-05	0.000527	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.16e-05	0.000525	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.15e-05	0.000524	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—urinary bladder cancer	7.1e-05	0.00052	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—urinary bladder cancer	7.04e-05	0.000516	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—urinary bladder cancer	6.95e-05	0.000509	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.9e-05	0.000505	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—urinary bladder cancer	6.86e-05	0.000503	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.82e-05	0.000499	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—urinary bladder cancer	6.81e-05	0.000499	CcSEcCtD
Bosutinib—Pain—Epirubicin—urinary bladder cancer	6.75e-05	0.000494	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—urinary bladder cancer	6.7e-05	0.000491	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—urinary bladder cancer	6.67e-05	0.000488	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—urinary bladder cancer	6.67e-05	0.000488	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.65e-05	0.000487	CcSEcCtD
Bosutinib—ABCB1—seminal vesicle—urinary bladder cancer	6.53e-05	0.000396	CbGeAlD
Bosutinib—Dyspnoea—Doxorubicin—urinary bladder cancer	6.51e-05	0.000477	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—urinary bladder cancer	6.51e-05	0.000476	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.46e-05	0.000473	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—urinary bladder cancer	6.35e-05	0.000465	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.31e-05	0.000462	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—urinary bladder cancer	6.3e-05	0.000461	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—urinary bladder cancer	6.27e-05	0.000459	CcSEcCtD
Bosutinib—Pain—Doxorubicin—urinary bladder cancer	6.25e-05	0.000458	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—urinary bladder cancer	6.24e-05	0.000457	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—urinary bladder cancer	6.24e-05	0.000457	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—urinary bladder cancer	6.23e-05	0.0123	CbGdCrCtD
Bosutinib—Asthenia—Methotrexate—urinary bladder cancer	6.05e-05	0.000443	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.02e-05	0.000441	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.97e-05	0.000437	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—urinary bladder cancer	5.97e-05	0.000437	CcSEcCtD
Bosutinib—CYP3A4—female reproductive system—urinary bladder cancer	5.96e-05	0.000361	CbGeAlD
Bosutinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	5.94e-05	0.0117	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	5.94e-05	0.0117	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	5.94e-05	0.0117	CbGdCrCtD
Bosutinib—Urticaria—Doxorubicin—urinary bladder cancer	5.8e-05	0.000425	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—urinary bladder cancer	5.77e-05	0.000423	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—urinary bladder cancer	5.77e-05	0.000423	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—urinary bladder cancer	5.77e-05	0.000423	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—urinary bladder cancer	5.76e-05	0.0114	CbGdCrCtD
Bosutinib—ABCB1—epithelium—urinary bladder cancer	5.67e-05	0.000344	CbGeAlD
Bosutinib—Asthenia—Epirubicin—urinary bladder cancer	5.66e-05	0.000415	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—urinary bladder cancer	5.59e-05	0.000409	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—urinary bladder cancer	5.58e-05	0.000409	CcSEcCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	5.5e-05	0.0108	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	5.5e-05	0.0108	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	5.5e-05	0.0108	CbGdCrCtD
Bosutinib—Diarrhoea—Epirubicin—urinary bladder cancer	5.4e-05	0.000396	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—urinary bladder cancer	5.36e-05	0.000393	CcSEcCtD
Bosutinib—Rash—Methotrexate—urinary bladder cancer	5.32e-05	0.00039	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—urinary bladder cancer	5.31e-05	0.000389	CcSEcCtD
Bosutinib—Headache—Methotrexate—urinary bladder cancer	5.28e-05	0.000387	CcSEcCtD
Bosutinib—ABCB1—renal system—urinary bladder cancer	5.26e-05	0.000319	CbGeAlD
Bosutinib—Asthenia—Doxorubicin—urinary bladder cancer	5.24e-05	0.000384	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—urinary bladder cancer	5.22e-05	0.000382	CcSEcCtD
Bosutinib—ABCB1—urethra—urinary bladder cancer	5.17e-05	0.000313	CbGeAlD
Bosutinib—Pruritus—Doxorubicin—urinary bladder cancer	5.17e-05	0.000379	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—urinary bladder cancer	5.02e-05	0.000368	CcSEcCtD
Bosutinib—Nausea—Methotrexate—urinary bladder cancer	5.01e-05	0.000367	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—urinary bladder cancer	5e-05	0.000366	CcSEcCtD
Bosutinib—Rash—Epirubicin—urinary bladder cancer	4.98e-05	0.000365	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—urinary bladder cancer	4.97e-05	0.000364	CcSEcCtD
Bosutinib—Headache—Epirubicin—urinary bladder cancer	4.95e-05	0.000362	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—urinary bladder cancer	4.83e-05	0.000354	CcSEcCtD
Bosutinib—Nausea—Epirubicin—urinary bladder cancer	4.69e-05	0.000343	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—urinary bladder cancer	4.64e-05	0.00034	CcSEcCtD
Bosutinib—Rash—Doxorubicin—urinary bladder cancer	4.61e-05	0.000337	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—urinary bladder cancer	4.6e-05	0.000337	CcSEcCtD
Bosutinib—Headache—Doxorubicin—urinary bladder cancer	4.58e-05	0.000335	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—urinary bladder cancer	4.34e-05	0.000318	CcSEcCtD
Bosutinib—ABCB1—female reproductive system—urinary bladder cancer	4.22e-05	0.000256	CbGeAlD
Bosutinib—ABCB1—vagina—urinary bladder cancer	3.81e-05	0.000231	CbGeAlD
Bosutinib—ABCB1—lymph node—urinary bladder cancer	2.47e-05	0.00015	CbGeAlD
Bosutinib—SRC—Adaptive Immune System—HRAS—urinary bladder cancer	1.31e-06	5.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—urinary bladder cancer	1.31e-06	5.81e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CDKN1A—urinary bladder cancer	1.3e-06	5.79e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	1.3e-06	5.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PTEN—urinary bladder cancer	1.3e-06	5.78e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGFR3—urinary bladder cancer	1.29e-06	5.76e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—urinary bladder cancer	1.29e-06	5.75e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	1.29e-06	5.74e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—urinary bladder cancer	1.29e-06	5.73e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—urinary bladder cancer	1.29e-06	5.73e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—urinary bladder cancer	1.28e-06	5.72e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—urinary bladder cancer	1.28e-06	5.7e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—urinary bladder cancer	1.28e-06	5.7e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	1.28e-06	5.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	1.27e-06	5.67e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—SRC—urinary bladder cancer	1.27e-06	5.67e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—urinary bladder cancer	1.27e-06	5.66e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CDKN1A—urinary bladder cancer	1.27e-06	5.66e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.27e-06	5.66e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTEN—urinary bladder cancer	1.27e-06	5.65e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—urinary bladder cancer	1.27e-06	5.64e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—urinary bladder cancer	1.27e-06	5.63e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—urinary bladder cancer	1.26e-06	5.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—urinary bladder cancer	1.26e-06	5.61e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—urinary bladder cancer	1.26e-06	5.61e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—urinary bladder cancer	1.26e-06	5.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ESR1—urinary bladder cancer	1.26e-06	5.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—EP300—urinary bladder cancer	1.26e-06	5.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—urinary bladder cancer	1.25e-06	5.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-06	5.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—urinary bladder cancer	1.24e-06	5.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	1.24e-06	5.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—urinary bladder cancer	1.24e-06	5.54e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—urinary bladder cancer	1.24e-06	5.51e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EP300—urinary bladder cancer	1.24e-06	5.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—urinary bladder cancer	1.23e-06	5.48e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.23e-06	5.48e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	1.23e-06	5.48e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	1.23e-06	5.47e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—urinary bladder cancer	1.23e-06	5.46e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—urinary bladder cancer	1.22e-06	5.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—SRC—urinary bladder cancer	1.22e-06	5.43e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CDKN1A—urinary bladder cancer	1.22e-06	5.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.22e-06	5.42e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—urinary bladder cancer	1.22e-06	5.42e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—urinary bladder cancer	1.22e-06	5.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—urinary bladder cancer	1.21e-06	5.4e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EP300—urinary bladder cancer	1.21e-06	5.38e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—urinary bladder cancer	1.21e-06	5.38e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—urinary bladder cancer	1.21e-06	5.38e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—urinary bladder cancer	1.21e-06	5.36e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.21e-06	5.36e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SRC—urinary bladder cancer	1.2e-06	5.36e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	1.2e-06	5.33e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—urinary bladder cancer	1.2e-06	5.33e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.19e-06	5.28e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—urinary bladder cancer	1.18e-06	5.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-06	5.25e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	1.18e-06	5.24e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—SRC—urinary bladder cancer	1.18e-06	5.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—urinary bladder cancer	1.18e-06	5.23e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—urinary bladder cancer	1.17e-06	5.22e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	1.17e-06	5.22e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—urinary bladder cancer	1.17e-06	5.22e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—urinary bladder cancer	1.17e-06	5.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	1.17e-06	5.2e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—urinary bladder cancer	1.16e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—urinary bladder cancer	1.16e-06	5.18e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—urinary bladder cancer	1.16e-06	5.16e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—urinary bladder cancer	1.15e-06	5.13e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	1.15e-06	5.1e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	1.15e-06	5.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—urinary bladder cancer	1.15e-06	5.1e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.14e-06	5.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—urinary bladder cancer	1.14e-06	5.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.14e-06	5.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-06	5.05e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—urinary bladder cancer	1.13e-06	5.05e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.13e-06	5.04e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.13e-06	5.04e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-06	5.04e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—urinary bladder cancer	1.13e-06	5.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.13e-06	5.02e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.13e-06	5.02e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—urinary bladder cancer	1.13e-06	5.02e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CDKN1A—urinary bladder cancer	1.13e-06	5.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	1.13e-06	5.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—urinary bladder cancer	1.12e-06	5e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	1.12e-06	5e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—urinary bladder cancer	1.12e-06	4.99e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.12e-06	4.99e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	1.12e-06	4.99e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—urinary bladder cancer	1.12e-06	4.97e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—urinary bladder cancer	1.12e-06	4.97e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—urinary bladder cancer	1.12e-06	4.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	1.11e-06	4.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	1.11e-06	4.94e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	1.11e-06	4.93e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—urinary bladder cancer	1.11e-06	4.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CREBBP—urinary bladder cancer	1.1e-06	4.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-06	4.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—urinary bladder cancer	1.09e-06	4.87e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.09e-06	4.87e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—urinary bladder cancer	1.09e-06	4.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—urinary bladder cancer	1.09e-06	4.87e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	1.09e-06	4.85e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—urinary bladder cancer	1.09e-06	4.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—urinary bladder cancer	1.09e-06	4.84e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.09e-06	4.83e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.08e-06	4.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	1.08e-06	4.82e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—urinary bladder cancer	1.08e-06	4.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	1.08e-06	4.81e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—urinary bladder cancer	1.08e-06	4.81e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—urinary bladder cancer	1.08e-06	4.8e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—urinary bladder cancer	1.08e-06	4.79e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-06	4.78e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—urinary bladder cancer	1.07e-06	4.77e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—urinary bladder cancer	1.07e-06	4.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-06	4.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-06	4.75e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—urinary bladder cancer	1.07e-06	4.75e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.06e-06	4.74e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.06e-06	4.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-06	4.72e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-06	4.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—urinary bladder cancer	1.06e-06	4.7e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	1.06e-06	4.7e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-06	4.7e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—urinary bladder cancer	1.05e-06	4.7e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—urinary bladder cancer	1.05e-06	4.69e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SRC—urinary bladder cancer	1.05e-06	4.68e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-06	4.64e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—urinary bladder cancer	1.03e-06	4.6e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—urinary bladder cancer	1.03e-06	4.59e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—urinary bladder cancer	1.03e-06	4.59e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	1.03e-06	4.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	1.03e-06	4.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	1.02e-06	4.53e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—urinary bladder cancer	1.02e-06	4.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—urinary bladder cancer	1.01e-06	4.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—urinary bladder cancer	1.01e-06	4.5e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—urinary bladder cancer	1.01e-06	4.48e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.01e-06	4.47e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1e-06	4.45e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—urinary bladder cancer	9.97e-07	4.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RHOA—urinary bladder cancer	9.96e-07	4.43e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—urinary bladder cancer	9.94e-07	4.43e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—urinary bladder cancer	9.92e-07	4.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—urinary bladder cancer	9.89e-07	4.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—urinary bladder cancer	9.89e-07	4.4e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—urinary bladder cancer	9.89e-07	4.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	9.88e-07	4.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—urinary bladder cancer	9.84e-07	4.38e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—urinary bladder cancer	9.8e-07	4.36e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—urinary bladder cancer	9.74e-07	4.33e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—urinary bladder cancer	9.62e-07	4.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	9.55e-07	4.25e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—urinary bladder cancer	9.49e-07	4.22e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	9.44e-07	4.2e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—urinary bladder cancer	9.43e-07	4.19e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	9.41e-07	4.19e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—urinary bladder cancer	9.34e-07	4.16e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—urinary bladder cancer	9.33e-07	4.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—urinary bladder cancer	9.31e-07	4.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	9.27e-07	4.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	9.24e-07	4.11e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—urinary bladder cancer	9.22e-07	4.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—urinary bladder cancer	9.22e-07	4.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	9.22e-07	4.1e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	9.2e-07	4.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	9.2e-07	4.09e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—urinary bladder cancer	9.13e-07	4.06e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.1e-07	4.05e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—urinary bladder cancer	9.01e-07	4.01e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	9e-07	4e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	9e-07	4e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—urinary bladder cancer	8.97e-07	3.99e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	8.93e-07	3.98e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	8.9e-07	3.96e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	8.88e-07	3.95e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—urinary bladder cancer	8.87e-07	3.95e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—urinary bladder cancer	8.86e-07	3.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—urinary bladder cancer	8.82e-07	3.92e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	8.81e-07	3.92e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—urinary bladder cancer	8.79e-07	3.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—urinary bladder cancer	8.75e-07	3.89e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—urinary bladder cancer	8.71e-07	3.88e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—urinary bladder cancer	8.67e-07	3.86e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—urinary bladder cancer	8.63e-07	3.84e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—urinary bladder cancer	8.62e-07	3.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—urinary bladder cancer	8.59e-07	3.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—urinary bladder cancer	8.55e-07	3.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	8.5e-07	3.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—urinary bladder cancer	8.47e-07	3.77e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	8.47e-07	3.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—urinary bladder cancer	8.36e-07	3.72e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	8.32e-07	3.7e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—urinary bladder cancer	8.28e-07	3.68e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	8.24e-07	3.67e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—urinary bladder cancer	8.19e-07	3.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—urinary bladder cancer	8.15e-07	3.63e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—urinary bladder cancer	8.15e-07	3.63e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.11e-07	3.61e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—urinary bladder cancer	7.94e-07	3.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—urinary bladder cancer	7.91e-07	3.52e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—urinary bladder cancer	7.88e-07	3.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—urinary bladder cancer	7.86e-07	3.5e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.79e-07	3.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—urinary bladder cancer	7.74e-07	3.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—urinary bladder cancer	7.66e-07	3.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.59e-07	3.38e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	7.55e-07	3.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—urinary bladder cancer	7.5e-07	3.34e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—urinary bladder cancer	7.4e-07	3.29e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—urinary bladder cancer	7.4e-07	3.29e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	7.38e-07	3.29e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—urinary bladder cancer	7.33e-07	3.26e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—urinary bladder cancer	7.28e-07	3.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—urinary bladder cancer	7.24e-07	3.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	7.22e-07	3.22e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	7.22e-07	3.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	7.08e-07	3.15e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	7.07e-07	3.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.05e-07	3.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.97e-07	3.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.97e-07	3.1e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—urinary bladder cancer	6.96e-07	3.1e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—urinary bladder cancer	6.93e-07	3.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	6.82e-07	3.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.68e-07	2.97e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.56e-07	2.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—urinary bladder cancer	6.54e-07	2.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—urinary bladder cancer	6.39e-07	2.84e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.38e-07	2.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—urinary bladder cancer	6.29e-07	2.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.16e-07	2.74e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	6.06e-07	2.7e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—urinary bladder cancer	6.04e-07	2.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	6.02e-07	2.68e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	5.8e-07	2.58e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.56e-07	2.48e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—urinary bladder cancer	5.37e-07	2.39e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—urinary bladder cancer	5.31e-07	2.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—urinary bladder cancer	5.13e-07	2.28e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5e-07	2.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.8e-07	2.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.93e-07	1.75e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.43e-07	1.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.27e-07	1.45e-06	CbGpPWpGaD
